Bris­tol My­er­s' block­buster-to-be Re­blozyl scores a PhI­II win

Bris­tol My­ers Squibb un­veiled a sur­prise vic­to­ry on Mon­day for its po­ten­tial $4 bil­lion-per-year drug Re­blozyl, with the bio­phar­ma an­nounc­ing that it hit a pri­ma­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER